Results 191 to 200 of about 8,158 (292)

Impaired Brain Incretin and Gut Hormone Expression in Human Alcohol-Related Brain Damage: Opportunities for Therapeutic Targeting. [PDF]

Biomolecules
de la Monte SM, Tong M, Carlson RI, Sutherland G.   +3 more
europepmc   +1 more source

Rates of, Reasons for, and Reactions to Discontinuation of GLP‐1 Receptor Agonists: A Narrative Review

Diabetes, Obesity and Metabolism, Volume 28, Issue 8, Page 6533-6549, August 2026.
ABSTRACT GLP‐1RAs are increasingly used for their glucose‐lowering and weight‐management effects, but many patients discontinue them. In this narrative review we aim to review real‐world, quantitative and qualitative GLP‐1RA discontinuation, adherence, and persistence evidence as it aligns with an established conceptual framework for understanding ...
Henry D. Heisey, L. Parker Gregg, Christopher D. Verrico, Dennis T. Villareal, Terri L. Fletcher   +4 more
wiley   +1 more source

Pathophysiology and the Therapeutic Potential of Incretins in Domestic Animals Suffering from Diabetes Mellitus Type 2

Diabetes melitus jedan je od najčešćih endokrinih poremećaja kod domaćih životinja, posebno mačaka. Ova kronična metabolička bolest, koja se očituje smanjenom sposobnošću tijela da regulira razinu glukoze u krvi, ima višestruke uzroke, uključujući ...
Milanović, Nikolina
core  

Sleep and circadian effects on the incretin system. [PDF]

Curr Sleep Med Rep
Yuan RK, Zitting KM.
europepmc   +1 more source

Incretin mimetic [PDF]

, 2020
openaire   +1 more source

Risk of Psychiatric Worsening With GLP‐1 Receptor Agonist Use in Patients With Type 2 Diabetes and Treated Depression

Diabetes, Obesity and Metabolism, Volume 28, Issue 8, Page 7048-7057, August 2026.
ABSTRACT Aims To compare 1‐year psychiatric outcomes after GLP‐1 receptor agonist (GLP‐1 RA) versus sodium‐glucose cotransporter‐2 inhibitor (SGLT2i) initiation in patients with type 2 diabetes and treated depression. Materials and Methods We conducted a retrospective active‐comparator, new‐user cohort study using electronic health records from the ...
Yu Chang, Ming‐Hong Hsieh, Po‐Chung Ju, Cheng‐Chen Chang   +3 more
wiley   +1 more source

Is there still room for pioglitazone in contemporary type 2 diabetes management? [PDF]

Cardiovasc Diabetol
Caruso I.
europepmc   +1 more source

The broadening incretin concept

Gastroenterology, 1980
openaire   +2 more sources

Increased autoantibodies against incretin indicate poor prognosis in patients with diabetes. [PDF]

Sci Rep
Takemoto M, Zhang BS, Hayashi A, Yamagata H, Yoshida Y, Koshizaka M, Onishi S, Yamaga M, Yoshida T, Hashimoto T, Ohtake N, Ishikawa T, Takizawa H, Hiwasa T.   +13 more
europepmc   +1 more source

Acute GIP and GLP‐1 Administration Exerts Differential Metabolic Effects in Totally Pancreatectomised Individuals

Diabetes, Obesity and Metabolism, Volume 28, Issue 8, Page 7280-7290, August 2026.
ABSTRACT Aims While being recognised for stimulating pancreatic insulin secretion, GIP and GLP‐1 exert various extrapancreatic effects relevant in the context of incretin‐based therapies. Here, we evaluated the extrapancreatic effects of GIP and GLP‐1, separately and combined, on postprandial physiology in totally pancreatectomised individuals ...
Liva S. L. Krogh, Maja B. Hansen, Natasha C. Bergmann, Carsten P. Hansen, Bolette Hartmann, Jens J. Holst, Filip K. Knop, Asger B. Lund, Lærke S. Gasbjerg   +8 more
wiley   +1 more source